These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 1687522)
1. Immunohistochemical assessment of tumour behaviour and patient prognosis in human breast cancer. Barnes DM Dis Markers; 1991; 9(3-4):159-65. PubMed ID: 1687522 [No Abstract] [Full Text] [Related]
2. Oncogenic proteins and prognostic correlations in breast cancer. Molina R; Filelia X; Segui MA; Climent MA; Pérez-Picañol E; Alonso C; Jo J; Ojeda B; Tandon AK; Ballesta AM In Vivo; 1993; 7(6B):585-9. PubMed ID: 7910764 [No Abstract] [Full Text] [Related]
3. c-erbB-2 oncogene related to p53 expression, cell proliferation and prognosis in breast cancer. Lipponen HJ; Aaltomaa S; Syrjänen S; Syrjänen K Anticancer Res; 1993; 13(4):1147-52. PubMed ID: 8102517 [TBL] [Abstract][Full Text] [Related]
4. Oncogenes and antioncogenes in human breast carcinoma. Leslie KO; Howard P Pathol Annu; 1992; 27 Pt 1():321-42. PubMed ID: 1346552 [No Abstract] [Full Text] [Related]
5. Oncogenes and tumour suppressor genes in breast cancer. Eccles MR; Phipps RF Br J Hosp Med; 1993 Nov 3-16; 50(9):529-36. PubMed ID: 7904528 [TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical expression of p53 and c-erbB2 proteins in breast cancer in Egypt. el-A Helal T; Khalifa A; Kamel AS Anticancer Res; 2000; 20(3B):2145-50. PubMed ID: 10928168 [TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical detection of p53 protein expression in breast cancer in young Kuwaiti women. Temmim L; Baker H; Sinowatz F Anticancer Res; 2001; 21(1B):743-8. PubMed ID: 11299837 [TBL] [Abstract][Full Text] [Related]
8. Molecular analyses of in situ breast cancer. Stratton MR; Collins N; Lakhani S; Sloane J Eur J Cancer Prev; 1993 Nov; 2 Suppl 3():123. PubMed ID: 7905313 [No Abstract] [Full Text] [Related]
9. Immunohistochemical analysis of expression of a 65 kDa oncofetal protein (p65), epidermal growth factor receptor (EGFR), oncogene c-erb B2 and tumor suppressor gene p53 protein products in breast cancer patients. Niewiadomska H; Mirowski M; Stempień M; Błoński JZ; Czyz W; Switalska J; Matyga E; Hanausek M; Wierzbicki R Neoplasma; 2000; 47(1):8-14. PubMed ID: 10870681 [TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical co-expression of c-erbb-2/Neu oncoprotein, altered tumour suppressor (p53) protein, EGF-R and EMA in histological subtypes of infiltrating duct carcinoma of the breast. Sharma BK; Ray A; Kaur S; Gupta S Indian J Exp Biol; 1999 Mar; 37(3):223-7. PubMed ID: 10641149 [TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of the co-expression of p53 and c-erbB-2 proteins in breast cancer. Nakopoulou LL; Alexiadou A; Theodoropoulos GE; Lazaris AC; Tzonou A; Keramopoulos A J Pathol; 1996 May; 179(1):31-8. PubMed ID: 8691341 [TBL] [Abstract][Full Text] [Related]
13. Prognostic value of genomic alterations in minimal residual cancer cells purified from the blood of breast cancer patients. Austrup F; Uciechowski P; Eder C; Böckmann B; Suchy B; Driesel G; Jäckel S; Kusiak I; Grill HJ; Giesing M Br J Cancer; 2000 Dec; 83(12):1664-73. PubMed ID: 11104564 [TBL] [Abstract][Full Text] [Related]
14. Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients. Kröger N; Milde-Langosch K; Riethdorf S; Schmoor C; Schumacher M; Zander AR; Löning T Clin Cancer Res; 2006 Jan; 12(1):159-68. PubMed ID: 16397038 [TBL] [Abstract][Full Text] [Related]
15. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2. Haitel A; Posch B; El-Baz M; Mokhtar AA; Susani M; Ghoneim MA; Marberger M J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901 [TBL] [Abstract][Full Text] [Related]
16. Tumour markers in breast carcinoma correlate with grade rather than with invasiveness. Wärnberg F; Nordgren H; Bergkvist L; Holmberg L Br J Cancer; 2001 Sep; 85(6):869-74. PubMed ID: 11556839 [TBL] [Abstract][Full Text] [Related]
17. Downregulation of the potential suppressor gene IGFBP-rP1 in human breast cancer is associated with inactivation of the retinoblastoma protein, cyclin E overexpression and increased proliferation in estrogen receptor negative tumors. Landberg G; Ostlund H; Nielsen NH; Roos G; Emdin S; Burger AM; Seth A Oncogene; 2001 Jun; 20(27):3497-505. PubMed ID: 11429696 [TBL] [Abstract][Full Text] [Related]
18. [Prognostic, therapeutic, exploratory tool for carcinogenesis: what is the role of ERBB-2 in breast cancer?]. Penault-Llorca F; Jacquemier J Ann Pathol; 1999 Apr; 19(2):103-15. PubMed ID: 10349474 [No Abstract] [Full Text] [Related]
19. ras, c-myc and c-erbB-2 oncoproteins in human breast cancer. Spandidos DA; Yiagnisis M; Papadimitriou K; Field JK Anticancer Res; 1989; 9(5):1385-93. PubMed ID: 2574023 [TBL] [Abstract][Full Text] [Related]
20. Relationship of p53 and c-erbB-2 expression to histopathological features, Helicobacter pylori infection and prognosis in gastric cancer. Shun CT; Wu MS; Lin JT; Chen SY; Wang HP; Lee WJ; Wang TH; Chuang SM Hepatogastroenterology; 1997; 44(14):604-9. PubMed ID: 9164544 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]